Journal Scans
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Risedronate Prevents Aromatase Inhibitor−Induced Bone Loss
C Van Poznak, RA Hannon, JR Mackey, M Campone, JP Apffelstaedt, G Clack, D Barlow, A Makris, R Eastell
20100011
2010 Jan 11
J Clin Oncol
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
J Clin Oncol. 2010 Jan 11; Epub ahead of print, C Van Poznak, RA Hannon, JR Mackey, M Campone, JP Apffelstaedt, G Clack, D Barlow, A Makris, R Eastell
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Aromatase inhibitors, which include anastrozole, exemestane, and letrozole, are used as standard adjuvant therapy for postmenopausal women with hormone-receptor (HR)–positive early breast cancer. Because these agents reduce circulating estrogen, their use raises concerns about accelerated bone loss and increased risk of fracture. Bone loss associated with estrogen deficiency can be managed with bisphosphonates (e.g. risedronate sodium). In this phase III/IV study—designated as SABRE (Study of Anastrozole...
